A national pharmaceutical industry group headquartered in Shanghai
Shanghai Pharmaceutical Group Corporation Limited (the Company) (HKSE stock code: 02607; SSE stock code: 601607) is a national pharmaceutical industry group headquartered in Shanghai. The Company's main business covers pharmaceutical research and development and manufacturing, distribution and retailing, with an operating income of 105.5 billion yuan in 2015, the Company's overall ranking is among the best in China, and it is one of the few listed pharmaceutical companies in China with a leading position in both the pharmaceutical products and distribution markets, selected as a sample stock of the SSE 180 Index and the CSI 300 Index, and its H shares are selected as a constituent stock of the Hang Seng Index, a constituent stock of the Morgan Stanley China Index ( (MSCI).
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchIndustrials, Financials, Consumer Discretionary
Tech for Global, Globalization Footprints of the Established and the New
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM